Pharmaceuticals

Global Duchenne Muscular Dystrophy Market Projected to Expand at 8.2% CAGR by 2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Duchenne Muscular Dystrophy Market Expected To Become By 2029 Compared With Its 2025 Level?

The duchenne muscular dystrophy market has demonstrated significant expansion in recent years. It is projected to increase from $1.16 billion in 2024 to $1.25 billion in 2025, at a compound annual growth rate (CAGR) of 7.9%. This historical growth can be attributed to factors such as genetic understanding and diagnostic advances, clinical trial progress, patient advocacy and awareness, orphan drug designation and incentives, and collaborative research initiatives.

The duchenne muscular dystrophy market size is anticipated to undergo substantial growth over the next few years. It is predicted to expand to ” $1.72 billion by 2029, achieving a compound annual growth rate (CAGR) of 8.2%. This expected expansion is driven by factors such as emerging gene therapies, precision medicine approaches, increased access to treatments, long-term follow-up studies, and regulatory advancements. Significant trends characterizing this period include the integration of digital health technologies, continued technological advancements in therapeutics, the development of gene therapies and genetic medicines, robust regulatory support for orphan drugs, and the evolution of precision medicine approaches.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10368&type=smp

Which Industry Drivers Are Expected To Accelerate The Duchenne Muscular Dystrophy Market From 2025 To 2029?

The rising incidence of chronic diseases is anticipated to drive the future growth of the Duchenne muscular dystrophy market. A chronic disease is defined as a health condition or issue presenting with long-lasting symptoms for a minimum of one year. The Duchenne muscular dystrophy contributes to the overall prevalence of chronic diseases by addressing the specific therapeutic requirements of individuals afflicted with this genetic disorder, thereby emphasizing the broader importance of personalized medicine in managing and potentially reducing the impact of chronic conditions. For instance, in January 2023, according to the National Library of Medicine, a US-based government agency, the count of individuals in the US aged 50 and older experiencing at least 1 chronic condition is projected to reach 142.66 million by 2050. Consequently, the increasing prevalence of chronic diseases is a key factor propelling the growth of the Duchenne muscular dystrophy market.

Which Key Segments Fueling The Duchenne Muscular Dystrophy Market?

The duchenne muscular dystrophy market covered in this report is segmented –

1) By Therapy: Mutation Suppression, Exon Skipping Approach

2) By Therapeutic Class: Molecular Based Therapies, Steroid Therapy

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Mutation Suppression: Antisense Oligonucleotides (ASOs), Small Molecules, Gene Therapy

2) By Exon Skipping Approach: Exon-Skipping Therapies, Combination Therapies, Clinical Trials And Investigational Drugs

Which Trends Are Impacting The Duchenne Muscular Dystrophy Market?

Leading companies in the Duchenne muscular dystrophy market are developing technological advancements, notably in clinical trial design, to boost the efficiency and effectiveness of drug development processes, improve patient outcomes, and accelerate the approval of new therapies. Clinical trial design encompasses the organization and planning of a clinical trial to evaluate a new treatment’s safety and effectiveness, covering goal definition, participant selection, and the outlining of methods and analyses. For instance, in March 2024, Critical Path Institute (C-Path), a US-based non-profit organization, launched the DMD Clinical Trial Simulator (CTS). This innovative tool, created by C-Path’s Duchenne Regulatory Science Consortium, aims to optimize the design of efficacy studies for DMD therapies. Key features of the CTS include advanced modeling of functional test performance, the capability to simulate various scenarios, increased efficiency in trial design, and public accessibility via the C-Path website and the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). As such, it serves as a valuable resource for researchers and pharmaceutical companies engaged in DMD research.

Which Key Players Are Driving Competition In The Duchenne Muscular Dystrophy Market?

Major companies operating in the duchenne muscular dystrophy market include Pfizer Inc., GlaxoSmithKline plc, PerkinElmer Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma Inc., Rocket Pharmaceuticals Inc., Italfarmaco SpA, Solid Biosciences Inc., Avidity Biosciences Inc., Fulcrum Therapeutics Inc., Akashi Therapeutics Inc., WAVE Life Sciences Ltd., Capricor Therapeutics Inc., Santhera Pharmaceuticals Holding, Armagen Technologies Inc., Dyne Therapeutics Inc., Benitec Biopharma Limited, Edgewise Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-global-market-report

What Are The Regional Market Dynamics Impacting The Duchenne Muscular Dystrophy Industry?

North America was the largest region in the Duchenne muscular dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global duchenne muscular dystrophy market during the forecast period. The regions covered in the duchenne muscular dystrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Duchenne Muscular Dystrophy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=10368&type=smp

Browse Through More Reports Similar to the Global Duchenne Muscular Dystrophy Market 2025, By The Business Research Company

Generic Musculoskeletal Disorders Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/generic-musculoskeletal-disorders-drugs-global-market-report

Muscle Relaxant Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/muscle-relaxant-drugs-global-market-report

Womens Health Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/womens-health-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795